Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 2, 1996, Pages 982-990

  Wienkers, Larry C ^a   Steenwyk, Rick C ^a   Sanders, Phillip E ^a   Pearson, Paul G ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; FURAFYLLINE; KETOCONAZOLE; MEPHENYTOIN; QUINIDINE; SULFAPHENAZOLE; TIRILAZAD; TROLEANDOMYCIN;

ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL; SUBARACHNOID HEMORRHAGE;

ANTIOXIDANTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PREGNATRIENES; STEROID HYDROXYLASES;

EID: 0030431440     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. ANDERSON, D. K., BRAUGHLER, J. M., HALL, E. D., WATERS, T. R., MCCALL, J M. AND MEANS, E. D.: Effect of treatment with U-74006F on neurological outcome following experimental model of spinal cord injury. J. Neurosurg. 69: 562-567, 1988.
2. AUSTIN, K. L., MATHER, L. E., PHILPOT C. R. AND MCDONALD, P. J.. Intersubject and dose-related variability after intravenous adminstration of erythromycin. Br. J. Clin. Pharmacol. 10: 213-219, 1980.
3. BOMBARDT, P. A., BREWER, J. E., JOHNSON, M. G.: Protein binding of tirilazad (U-74006F) in human, Sprague-Dawley rat, beagle dog and cynomolgus monkey serum. J. Pharmacol. Exp. Ther. 269: 145-150, 1994.
4. BRAUGHLER, J. M., HALL, E. D., JACOBSON, E. J., MCCALL, J. M. AND MEANS, E. D.: The 21-aminosteroids: Potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs Future 14: 143-152, 1989.
5. BROWNE, T. R., SZABO, G. K., EVANS, J. E., EVANS, B. A., GREENBLATT, D. J. AND MIKATI, M. A.: Carbamazepine increases phenytoin serum concentration and reduces phenytoin clearance. Neurology 38: 1146-1150, 1988.
6. COMBALBERT, J., FABRE, I., FABRE, G., DALET, I., DERANCOURT, J., CANO, J. P AND MAUREL, P.: Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450III gene subfamily. Drug Metab. Dispos. 17: 197-207, 1989.
7. FIRST, M. R., SCHROEDER, T J., ALEXANDER, J. W., STEPHENS, G. W., WEISKITTEL, P., MYRE, S. A. AND PESCE, A. J.: Cyclosporine dose reduction by ketoconazole adminstration in renal transplant recipients. Transplantation 51: 365-370, 1991.
8. FLEISHAKER, J C., PETERS, G. R. AND CATHCART, K. S : Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I Single dose administration. J. Clin. Pharmacol. 33: 175-181, 1993.
9. FLEISHAKER, J. C., HULST, L. K. AND PETERS, G. R.: The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. Clin. Pharmacol. Ther. 56: 389-397, 1994a.
10. FLEISHAKER, J. C., HULST, L. K. AND PETERS, G. R.: Multiple dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers. International J. Clin. Pharmacol. 54: 402-414, 1994b.
11. FLEISHAKER, J. C., HULST, L. K. AND PETERS, G. R.: Lack of interaction between cimetidine and tirilazad mesylate. Pharm. Res. 11: 341-344, 1994c.
12. FLEISHAKER, J. C., PEARSON, P. G., WIENKERS, L. C., PEARSON, L. K. AND PETERS, G. R.. Biotransformation of tirilazad in human: 2. Effects of ketoconazole on tirilazad clearance and oral bioavailibility. J. Pharmacol. Exp. Ther. 277: 000-000, 1996.
13. FREEMAN, D. J., LAUPACIS, A., KEOWN, P. A., STILLER, C. R. AND CARRUTHERS, S. G.: Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br. J. Clin. Pharmacol. 18: 887-893, 1984.
14. GUENGERICH, F. P., MULLER-ENOCH, D. AND BLAIR, I. A.: Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30: 287-295, 1986
15. GUENGERICH, F. P.: Mechanism-based inactivation of human microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3: 363-371, 1990.
16. HALL, E. D., YONKERS P. A., MCCALL, J. M. AND BRAUGHLER, J. M.: Effects of the 21- aminosteroid U-74006F on experimental head injury in mice. J. Neurosurg. 68: 456-461, 1988a.
17. HALL, E. D., BERRY, K. P. AND BRAUGHLER, J. M.: The 21-aminosteroid lipid peroxidation inhibitor U-74006F protects against cerebral ischemia in gerbils Stroke 19: 997-1002, 1988b.
18. HENRICSSON, S. AND LINDHOLM, A.: Inhibition of cyclosporine metabolism by other drugs in vitro. Transplant. Proc 20: 569-571, 1988.
19. HULST, L. K., FLEISHAKER, J. C., PETERS, G. R., HARRY, J. D., WRIGHT, M., WARD, P.: Effect of age and gender on tirilazad pharmacokinetics in humans. Clin. Pharmacol. Ther. 55: 378-374, 1994.
20. HUNT, C. M , WESTERKAM, W. R. AND STAVES, G M.: Effect of age and gender on the activity of human hepatic CYP3A. Biochem. Pharmacol. 44: 275-283, 1992.
21. JACOBSEN, E. J., BUNDY, G. L. AND WYNALDA, M. A.: U.S. Patent, Neurologically active aminosteroids, in press, 1996.
22. JACOLOT, F., SIMON, I. AND DREANO, Y.: Identification of the cytochrome P450III family as the enzyme involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41: 1911-1919, 1991.
23. KASSELL, N. F., HALEY, E. C., APPERSON-HANSEN, C., ALVES, W. M. AND THE PARTICIPANTS: A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage a cooperative study in Europe/Australia/New Zealand. J. Neurosurg., in press.
24. KANAMURA, K., WEIR, B. K. A., FINDALY, J. M., GRACE, M. AND MACDONALD, R. L.: A dosage study of the effect of the 21-aminosteroid U-74006F on chronic cerebral vasospasm in a primate model. Neurosurgery 27: 29-38, 1990.
25. KRONBACH, T.: Bufurol, dextromethorphan and, debrisoquine as prototype substrates for human P-450IID6. Methods Enzymol. 206: 509-517, 1991.
26. KRONBACH, T., FISHER, V. AND MEYER, U. A.: Cyclosporine metabolism in human liver. Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther 43: 630-635, 1988.
27. KUNZE, K. L. AND TRAGER, W. F.: Isoform selective mechanism-based inhibition of human cytochrome P-450 1A2 by furafylline. Chem. Res. Toxicol. 6: 649-656, 1993.
28. LEE, H. J. AND WILSON, I. B.: Enzymatic parameters of V and Km. Biochim. Biophys. Acta. 242: 519-522, 1971.
29. LEW, K. H., LUDWIG, E. L., MILAD, M. A., DONOVAN, K., MIDDLETON, E., FERRY, J. J. AND JUSKO, W. J.: Gender-based effects on methylprednisolone pharmacokinetics pharmacodynamics. Clin. Pharmacol. Ther. 54: 402-414, 1989.
30. MEFFIN, P J., BROOKS, P. M AND SALLUSTIO, B. C.: Alterations in prednisolone dispostion as a result of time of adminstration, gender and dose. Br. J. Clin. Pharmacol. 17: 395-104, 1984.
31. MEIER, U. T., DAYER, P., MALE, P. J., KRONBACH, T. AND MEYER, U. R.: Mephenytoin hydroxylation polymorphism: Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin. Pharmacol. Ther. 38: 488-494, 1985.
32. NALINE, E., FLOUVAT, B., ADVENIER, C. AND PAYS, M.: Determination of theophylline and its metabolites in plasma and urine by reverse- phase liquid chromatography using an amine modifier. J. Chromatogr. 419: 177-189, 1987.
33. PATTON, P. R., BRUNSON, M. E., PRAFF, W. W., HOWARD, R. J., PETERSON, J. C., RAMOS, E. L. AND KARLIX, J. L.: A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation 57: 889-892, 1994.
34. PEARCE, R., GREENWAY, D AND PARKINSON, A.: Species differences and interindividual variation in liver microsomal cytochrome P-450 2A enzymes: Effects on coumarin, dicoumarol, and testosterone oxidation. Arch. Biochem. Biophys. 298: 211-225, 1992.
35. PERROT, N., NALPAS, B., YANG, C. S. AND BEAUNE, P. H.: Modulation of cytochrome P-450 isozymes in human liver, by ethanol and drug intake. Eur. J. Clin. Invest. 19: 549-555, 1989.
36. PETER, R., BOCKER, H., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. AND YANG, C. S.: Hydroxylation of chlorzoxazone as a specific probe for human cytochrome P-450IIE1. Chem. Res. Toxicol. 3: 566-573, 1990.
37. PICHARD, L., FABRE, L., FABRE, I., DOMERIQUE, G., AUBERT, B S., MOURAD, G. AND MAUREL, P.: Cyclosporine A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (Cyclosporine A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18: 595-606, 1990.
38. RELLING, M. V., AOYAMA, T., GONZALES, F. J AND MEYER, U. R.: Tolbutamide and mephenytoin hydroxylation by cytochrome P-450s in the 2C subfamily. J. Pharmacol. Exp. Ther. 252: 442-427, 1990.
39. SESARDIC, D., BOOBIS, A. R., EDWARDS, R. J. AND DAVIES, D. S.: A form of cytochrome P-450 in man, orthologous to form d in the rat, catalyses the O-demethylation of phenacetin and is inducible by smoking. Br. J. Clin. Pharmacol. 26: 363-372, 1988.
40. SCHELLENS, J. H. M., VAN DER WART, J. H. F., BRUGMAN, M. AND BRELMER, D. D.: Influence of enzyme induction and inhibition on the oxidation of nifedipine, spartiene, mephenytoin and antipyrine in humans as assessed by a coctail study design. J. Pharmacol. Exp. Ther. 249: 638-645, 1989.
41. STREEPER, R. T., SANDERS, P. E., PEARSOS, P. G., ZHAO, Z., STEENWYK, R. C., HAUER, M. J. AND VRBANAC, J. J.. The use of 2,4-dipyrrolidinylpyrimidine as a model to facilitate the characterization of metabolites of tirilazad. Proceedings of the 42nd ASMS Conference on Mass Spectrometry and Allied Topics, Chicago, Illinois, May 29-June 3, 1994, p 41.
42. 14C]-tirilazad mesylate to rabbit, dog, monkey and human. Pharm. Res. 9: suppl., S312, 1992.
43. THUMMEL, K. E., SHEN, D. D., PODOLL, T. D., KUNZE, K. L., TRAGER, W. F., BACCHI, C. E., MARSH, C. L., MCVICAR, J. P., BARR, D. M., PERKINS, J. D. AND CARITHERS, R. L.: Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variabilty after liver transplantation. J. Pharmacol. Exp. Ther. 271: 557-566, 1994.
44. VERONESE, M. E., MACKENZIE, P. I., DOECKE, C. J., MCMANUS, M. E., MINERS, J. O. AND BIRKETT, D. J.: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P502C9. Biochem. Biophys. Res. Commun. 175: 1112-1118, 1991
45. WAXMAN, D. J. AND AZAROFF, L.: Phenobarbital induction of cytochrome P-450 gene expression. Biochem. J. 281: 577-592, 1992.
46. WIENKERS, L. C., STEENWYK, R. C., MIZSAK, S. A. AND PEARSON, P. G.: In Vitro metabolism of tirilazad mesylate in male and female rats: contribution of cytochrome P450 2C11 and 5α-reductase. Drug Metab. Dispos. 23: 383-392, 1995.
47. WILKINSON, G. R. AND SHAND, D. G.: A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18: 377-390, 1975.
48. WOOD, A. W., RYAN, D. E., THOMAS, P. E. AND LEVIN, W.: Regio- and stereoselective metabolism of two C19 steroids by five highly purified and reconstituted rat hepatic cytochrome P-450 isozymes. J. Biol. Chem. 258: 8839-8847, 1983.
49. WRIGHTON, S. A., RING, B. A., WATKINS, P. B. AND VANDENBRANDEN, M.: Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 36: 97-105, 1989.
50. WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. AND VANDENBRANDEN, M.: Isolation and characterization of human liver cytochrome P-450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306: 240-245, 1993.
51. WRIGHTON, S. A., RING, B. A., WATKINS, P. B. AND VANDENBRANDEN, M.: Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 36: 97-105, 1989.
52. YONKERS, K. A., KANDO, J. C. AND COLE, J. O.: Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiatry 149: 587-595, 1992.